Loading...
Loading...
ENTX| Name | Value |
|---|---|
| Revenues | 57.0K |
| Cost of Revenue | 48.0K |
| Gross Profit | 9.0K |
| Operating Expense | 2,174.0K |
| Operating I/L | -2,165.0K |
| Other Income/Expense | 20.0K |
| Interest Income | 0.0K |
| Pretax | -2,145.0K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -2,145.0K |
Entera Bio Ltd. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of orally delivered large molecule therapeutics. The company's lead product candidates, EB612 and EB613, are in various stages of clinical trials for the treatment of hypoparathyroidism, osteoporosis, and non-union fractures. Entera Bio has a research collaboration and license agreement with Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company generates revenue through the development and potential commercialization of its innovative orally delivered large molecule therapeutics.
